322 related articles for article (PubMed ID: 22212664)
1. 2011 in reflection.
Mullard A
Nat Rev Drug Discov; 2012 Jan; 11(1):6-8. PubMed ID: 22212664
[No Abstract] [Full Text] [Related]
2. Society for Biomolecular Sciences--15th Annual Conference. Bioassay and technology innovation: 15 years of shaping drug discovery. 26-30 April 2009, Lille, France.
Napper AD
IDrugs; 2009 Jun; 12(6):363-5. PubMed ID: 19517316
[No Abstract] [Full Text] [Related]
3. Vas Narasimhan.
Narasimhan V; Mullard A
Nat Rev Drug Discov; 2016 Jan; 15(1):10-1. PubMed ID: 26718275
[No Abstract] [Full Text] [Related]
4. Marc Kirschner. Interview by Asher Mullard.
Kirschner M
Nat Rev Drug Discov; 2011 Dec; 10(12):894. PubMed ID: 22129982
[No Abstract] [Full Text] [Related]
5. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
6. Virtual drug discovery with the rise of Chinese CROs.
Zhang MQ
Drug Discov Today; 2010 Sep; 15(17-18):693-7. PubMed ID: 20685343
[No Abstract] [Full Text] [Related]
7. Could pharma open its drug freezers?
Mullard A
Nat Rev Drug Discov; 2011 Jun; 10(6):399-400. PubMed ID: 21629278
[No Abstract] [Full Text] [Related]
8. Drug development research: diabetes favored over cardiovascular disease?
Suckling K
Curr Opin Investig Drugs; 2009 Mar; 10(3):217-9. PubMed ID: 19333877
[No Abstract] [Full Text] [Related]
9. The conformational musings of a medicinal chemist.
Finch H
Drug Discov Today; 2014 Mar; 19(3):320-5. PubMed ID: 24184532
[TBL] [Abstract][Full Text] [Related]
10. Sources of innovation: an assessment of intellectual property.
Kinch MS; Raffo J
Drug Discov Today; 2015 May; 20(5):500-4. PubMed ID: 25499663
[TBL] [Abstract][Full Text] [Related]
11. The long march of antisense.
Jones D
Nat Rev Drug Discov; 2011 Jun; 10(6):401-2. PubMed ID: 21629279
[No Abstract] [Full Text] [Related]
12. The role of discovery DMPK scientists in industry: where do we go from here?
Moriwaki T
Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22531680
[No Abstract] [Full Text] [Related]
13. Trial watch: Clinical trial cycle times continue to increase despite industry efforts.
Martin L; Hutchens M; Hawkins C
Nat Rev Drug Discov; 2017 Mar; 16(3):157. PubMed ID: 28184041
[No Abstract] [Full Text] [Related]
14. An industrial perspective on contemporary applications of PBPK models in drug discovery and development.
Smith BJ
Biopharm Drug Dispos; 2012 Mar; 33(2):53-4. PubMed ID: 22407480
[No Abstract] [Full Text] [Related]
15. Development of novel IVD assays: a manufacturer's perspective.
Metcalfe TA
Scand J Clin Lab Invest Suppl; 2010; 242():23-6. PubMed ID: 20515272
[TBL] [Abstract][Full Text] [Related]
16. The future is much closer collaboration between the pharmaceutical industry and academic medical centers.
Vallance P; Williams P; Dollery C
Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455
[No Abstract] [Full Text] [Related]
17. To make better therapeutics, companies strive to increase the content of results and get them faster.
Szpir M
Biotechniques; 2007 Apr; 42(4 Suppl):S3-5. PubMed ID: 18798735
[No Abstract] [Full Text] [Related]
18. Trial watch: personalized medicines in late-stage development.
Milne CP; Garafalo S; Bryan C; McKiernan M
Nat Rev Drug Discov; 2014 May; 13(5):324-5. PubMed ID: 24781541
[No Abstract] [Full Text] [Related]
19. Partnering for therapeutics discovery.
Colvis CM; Devaney S; Brady LS; Hudson KL
Clin Pharmacol Ther; 2013 Jan; 93(1):24-5. PubMed ID: 23187876
[No Abstract] [Full Text] [Related]
20. Pharmacogenetics--pivotal to the future of the biopharmaceutical industry.
Foot E; Kleyn D; Palmer Foster E
Drug Discov Today; 2010 May; 15(9-10):325-7. PubMed ID: 20298799
[No Abstract] [Full Text] [Related]
[Next] [New Search]
